Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus (HIV) Positive Clear all
Completed No phase listed Observational

Prevalence of Hepatitis C Virus Infection in HIV-Infected Children

NCT00037076
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

NCT02515240
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
PPV23
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
19 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 15, 2026, 8:18 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

NCT00000920
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Ritonavir, Saquinavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 2 Interventional

The Healthy Life Choices Project in HIV-Positive Patients

NCT00017810
View directory record Official record
Conditions
Diarrhea, HIV Infections
Interventions
Dietary intervention, HIV Self-Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 2 Interventional

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

NCT00002399
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Not applicable Interventional

Enhancement of Connect to Protect® (C2P)

NCT01492816
View directory record Official record
Conditions
HIV Infection
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

NCT01536899
View directory record Official record
Conditions
HIV Positive, Marijuana Smoking
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 15, 2026, 8:18 AM EDT
Not listed Phase 2 Interventional

Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002099
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

C2P Mobilization Intervention (Pilot)

NCT00393575
View directory record Official record
Conditions
HIV Infections
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

NCT00005758
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational Results available

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Raltegravir, Dolutegravir, Colonoscopy with biopsy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 15, 2026, 8:18 AM EDT
Withdrawn No phase listed Observational

Immunology of HIV and Alcoholic Hepatitis

NCT03951662
View directory record Official record
Conditions
HIV/AIDS, Alcoholic Hepatitis
Interventions
Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational

Pericardial Fat and Inflammation in HIV Patients and Controls

NCT02399384
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus (HIV)
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

NCT00686205
View directory record Official record
Conditions
Healthy Donors, HIV Positive
Interventions
collection of follow-up sample based on PRISM HIV O Plus result
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
17 Years and older
Enrollment
24,111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Davenport, Iowa • Kansas City, Missouri • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Not applicable Interventional

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

NCT00002354
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

NCT00859677
View directory record Official record
Conditions
HIV Infections, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

NCT00004978
View directory record Official record
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 8:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border

NCT01152684
View directory record Official record
Conditions
HIV Positive
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 3 Interventional

Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women

NCT00197678
View directory record Official record
Conditions
HIV Infections
Interventions
Multivitamins-Multiples of RDA, Multivitamins-Single RDA
Dietary Supplement
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older · Female only
Enrollment
1,141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 15, 2026, 8:18 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 15, 2026, 8:18 AM EDT